Purpose: Copper-64 (Cu-64) and Galium-68 (Ga-68) radiolabeled DO3A and NODA conjugates of exendin-4 were used for preclinical imaging of pancreatic β cells via targeting of glucagon-like peptide-1 receptor (GLP-1R 
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D
iabetes mellitus (DM) is one of the most common chronic illnesses and the seventh leading cause of death in the USA [1] . Hyperglycemia, the main symptom of DM, results from insulin resistance and consequent increased Electronic supplementary material The online version of this article (doi:10.1007/s11307-015-0861-5) contains supplementary material, which is available to authorized users.
Correspondence to: Suzanne Lapi; e-mail: lapis@mir.wustl.edu (2016) insulin levels leading to eventual decline in pancreatic β cell mass (BCM) [2] . Until recently, the established method to quantify BCM requires an autopsy [3, 4] . Another drawback of the current postmortem technique is that the pancreas is one of the first organs to undergo autolysis [5] and thus the counts observed during autopsy may not be an accurate measure of β cell function prior to death. An in vivo method to quantify BCM, such as imaging using positron emission tomography (PET) or single photon emission computed tomography radioligands, would be valuable as a measure to determine disease progression in diabetic patients.
Glucagon-like peptide-1 (GLP-1) is a 30 amino acid hormone produced by intestinal enteroendocrine L cells that binds to the glucagon-like peptide-1 receptor (GLP-1R), a 463 amino acid class B G protein-coupled receptor known to be present in pancreatic β cells [6] [7] [8] . GLP-1 has been identified as an important mediator of the endocrine cycle by inducing the release of insulin in a glucose-dependent manner and has also been known to promote β cell proliferation in mammalian biological systems [9] . As the expression of GLP-1R in the pancreas is restricted to β cells, it is a good marker of β cell mass [10] [11] [12] . Therefore, a PET radioligand based on a GLP-1 agonist that targets the GLP-1R was sought as a potential non-invasive imaging agent for BCM.
The rapid in vivo degradation of GLP-1 by dipeptidylpeptidase IV (DPP-IV or CD 26) makes native GLP-1 an unreliable and short-lived compound for use as a PET tracer [13] . Therefore, more stable GLP-1R ligands such as exendin-4 have been used to produce PET tracers.
Exendin-4 is a 39-amino acid GLP-1R agonist, originally isolated from the venom of the lizard Heloderma suspectum (Gila monster) [14] , which is more metabolically stable than GLP-1. Synthetic exendin-4 is currently commercially available as Exenatide and is used as a treatment for DM. Exendin-(9-39)-amide is a truncated exendin-4 analogue that has also been investigated as an imaging agent as it is a potent GLP-1R antagonist [15, 16] . GLP-1 [12, 15, 17] and exendin-3 [18] analogues have also been investigated as possible peptide choices for imaging agents. The earliest attempt to radiolabel a GLP-1R agonist was in 1993 where exendin-4 was iodinated with I-125 by Göke et al. [15] . Over the years, various GLP-1R agonists/antagonists have been radiolabeled with I-125 [12, 15, 17, 19] , In-111 [20] [21] [22] , Tc-99 m [23] , F-18 [24, 25] , Cu-64 [10, [26] [27] [28] , and Ga-68 [27, 29] to study BCM and also tumors of β cell origin. With the availability of medical cyclotrons and 68 Ge/ 68 Ga generators, there has been an increased interest in GLP-1 PET tracers [10, 27, 29] . Most of the above work has highlighted the challenges associated with imaging BCM using GLP-1 analogues in small animals [10, 29, 30] . The first successful visualization of rodent pancreata with dynamic PET imaging was recently reported using a Cu-64-labeled GLP-1-based imaging agent [28] . Herein, we report the first use of exendin-4-derived radioligands to image rodent pancreata in vivo.
In most cases, the metal chelate conjugation of GLP-1 analogues has been performed with the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) macrocycle [10, 26, 29] . While the non-macrocyclic diethylene triamine pentaacetic acid (DTPA) [22] chelator has also been reported, the DOTA chelator is used more extensively since the latter has been shown to provide Cu-64 complexes with higher in vivo stability. Previous bifunctional chelator studies (BFC) have demonstrated 1,4,7,-triazacyclononane-1,4,7,-triacetic acid (NOTA) might potentially be a better chelator for some radio-metals [31, 32] . These studies investigated the effects of small structural changes on enhanced binding with Cu-64 and Ga-68 in in vivo systems [32] [33] [34] [35] . In the present study, we sought to compare the pancreatic uptake of DOTA and NOTA derivatives of exendin-4 (DO3A-VS-Cys 40 -exendin-4 and NODA-VSCys 40 -exendin-4; Fig. 1 ), using two different PET isotopes, one short lived (Ga-68, t 1/2 =68 min) and one with a relatively longer half-life (Cu-64, t ½ =12.7 h), in healthy rats.
Materials and Methods
General
All solvents and reagents were ultra-pure or trace metal grade and obtained from Sigma-Aldrich (St. Louis, MO) and used without further purification. Water (18 MΩ-cm resistivity) was obtained from a Millipore Integral 5 Milli-Q water system (Billerica, MA). Ga generator (Eckert & Ziegler) system. Ten to 12 ml of 0.1 M HCl was used to elute 68 GaCl 3 (1 ml/min) through a Strata X-C column [38] . The Strata X-C columns (Phenomenex, 30 mg/ml) were used without preconditioning. After eluting with 0.1 M HCL, the resin was dried with N 2 gas and the purified Ga-68 was obtained by desorbing the resin with 500 μl of 0.02 M HCl/98 % acetone [38] .
Typical labeling of DO3A-VS-and NODA-VS-Cys 40 -exendin-4 with Cu-64 was achieved by adding 10 μg of peptides to 37 MBq (1 mCi) 64 CuCl 2 in 200 μl of 0.1 M NH 4 OAc (pH 7). The reactions were incubated on a mixer with 800 rpm agitation at 37°C for 1 h.
For Ga-68, the same amount of peptide and activity was used in 200 μl of 1 M HEPES (pH 7) and incubated at 60°C for 15 min. Radiolabelled compounds were analyzed by TLC and highperformance liquid chromatography (HPLC). Radio-TLCs were developed with PBS and analyzed using a Bioscan 200 imaging scanner (Bioscan, Inc., Washington, DC). Radio-HPLC analysis were performed using Kinetex (Phenomenex) and XTerra (Waters) C-18 columns (5 μm, 4.6×150 mm I.D.) with a mobile phase of A: water (0.1 % TFA) and B: acetonitrile (0.1 % TFA), using a gradient of 30-80 % acetonitrile over 20 min with a 1 ml/min flow rate.
Serum Stability Studies
Ten microliters (∼100 μCi) of Cu-64/Ga-68-labeled peptides (DO3A-VS-and NODA-VS-Cys 40 -exendin-4) was added to 90 μl of rat serum (Sigma-Aldrich) and incubated at 37°C with agitation (500 rpm). Aliquots were removed at each time point and analyzed using radio-TLC and HPLC. For HPLC, analysis used an additional guard column, (Phenomenex SecurityGuard 3.00 mm I.D.) for the protection of the C-18 column. Stability of Ga-68 complexes was evaluated up to 3 h (0.5, 1, 2, and 3 h) and Cu-64 complexes up to 24 h (0.5, 1, 2, 4, and 24 h time points). All reactions were conducted in triplicate.
Biodistribution Studies
All animal experiments were performed in compliance with the Guidelines for Care and Use of Research Animals established by the Division of Comparative Medicine and the Animal Studies Committee of Washington University School of Medicine. Biodistribution studies were conducted in normal Sprague-Dawley (SD) male rats (Charles River Laboratories) of age 72-75 days weighing 350±40 g. For the imaging and biodistribution studies, the injection and blocking dose were diluted in saline solution (0.9 % NaCl, w/v) such that the amount of NH 4 OAc was 10 % or less (v/v). The compounds were evaluated in rats (n=3) which were injected via the tail vein with 100 μl of 0.925-1.85 MBq (25-50 μCi) of each radiotracer. Rats were anesthetized with 1-2 % isoflurane and euthanized by cervical dislocation. Organs of interest were harvested, and the amount of radioactivity in each organ was determined by gamma counting. The data were corrected for radioactive decay, and percent injected dose per gram (%ID/g) of tissue was calculated. All samples were standardized against a sample of the injected dose of radiolabeled analogues.
An initial pilot biodistribution was conducted with both [ -exendin-4 to determine an optimal imaging time point. This biodistribution was performed 10, 60, and 240 min after radiotracer injection. Based on this pilot study, subsequent biodistribution with all four conjugates were conducted at 1 h. Blocking studies were conducted using tail vein injections of 2.9 mg/kg body weight (adapted from Connolly et al. [10] ) unlabeled exendin-4 and exendin-(9-39)-amide 10 min prior to PET ligand administration. Post-imaging biodistribution studies were also performed immediately after small animal PET/X-ray computed tomography (CT). Rodents were euthanized, and organs of interest were collected, weighted, and radioactivity counted on a Beckman Gamma 8000 counter containing a NaI crystal (Beckman Instruments, Inc., Irvine, CA). Immediately after counting, the pancreata were subjected to autoradiography studies.
PET/CT Imaging Studies
Small animal PET/CT imaging studies were conducted in normal SD male rats. 1.85-3.70 MBq (50-100 μCi; 0.5-1.0 μg) of each compound was administrated via tail vein injection. Blocking studies were conducted by pre-injection with unlabeled exendin-4 analogues (exendin-4 and exendin-(9-39)-amide), 2.9 mg/kg body weight, intravenously, 10 min prior to radioligand injection. Rats were anesthetized with 1-2 % isoflurane/oxygen and imaged on an Inveon small animal PET/CT scanner (Siemens Medical Solutions). Dynamic images were collected for 1 h and reconstructed with the maximum a posteriori probability (MAP) algorithm followed by CT co-registration with the Inveon Research Workstation image display software (Siemens Medical Solutions, Knoxville, TN). Regions of interest (ROI) were selected from PET images with the CT anatomical guidelines, and the associated radioactivity was measured using Inveon Research Workstation software. The pancreas was identified in the CT images by following the edges of the stomach, spleen, and small intestines [39] . Standard uptake values (SUV) were calculated as nCi/cc×animal weight/injected dose.
Ex vivo Autoradiography Studies
Harvested fresh pancreata were immediately frozen by immersing in liquid nitrogen. Sectioning was carried out using a whole body cryo-microtome (Vibratome 8850). The tissues were adhered to the metal block holder using Cryo-M-Bed embedding compound (A-M systems) and frozen at −30°C on a Vibratome Cold Snap. These were cut into 20-40 μm sections and attached to adhesive glass slides (CFSA 1X, Leica Bio Systems) and were covered by adhesive tape (CryoJane Tape Transfer System). Prepared sections were exposed to a phosphor imaging plate (GE Healthcare Life Sciences). After exposing for 1, 4, and 12 h, the plates were scanned using phosphor imager plate scanner (Storm 840). The resulting images were processed using ImageQuant 5. Ga ]DO3A-VS and NODA-VS analogues, respectively, were obtained. For all complexes, the HPLC retention times were observed to be 6.1±0.1 min using 4.6×150 mm C18 column without a guard column (6.9±0.1 min with a guard column). We maintained the specific activity of 100.0 ±1.6 μCi/μg (518.7±3.7 Ci/mmol, 19.19±0.14 TBq/mmol) for all four complexes by using the same amount of radioactivity and mass. The radiolabeled compounds were obtained with high radiochemical purity and specific activity suitable for in vivo imaging and were used directly for preclinical applications without further purification.
In vitro stability studies for the Cu-64-and Ga-68-labeled DO3A-VS-and NODA-VS-Cys 40 exendin-4 analogues were determined by measuring the radioactive fraction of the parent compound at incubation intervals in rat serum at 37°C. As can be seen in Fig. 2 (complete data listed in Table S1 ), essentially no unbound metal was observed after the labeling. The [ 64 Cu]DO3A-VS and NODA-VS complexes were 83.1±0.6 % and 85.7±1.4 % intact in serum at the 24 h. At 3 h, the Ga-68-labeled compounds were 91.9 ±0.3 % and 92.9±1.0 % intact. In vitro stability of the peptide was also monitored using HPLC (λ=254, 266, and 280 nm) and observed to be 985 % intact at 24 h in rat serum. These results indicated that both Ga-68 and Cu-64 complexes remained intact over the time of evaluation.
Results of the pilot study with the Cu-64-radiolabeled complexes in selected organs at 10, 60, and 240 min after tracer administration are shown in Fig. 3 (Table S2 ). These data show that the highest pancreatic uptakes for both complexes were at 1 h, and thus, this time point was used for all additional studies. The main difference between the (Fig. 4, Table S3 ). Exendin-4 and exendin-(9-39)-amide reduced the radiolabeled signal by approximately 55 and 45 %, respectively, in the pancreas (with uptakes of 0.051 ±0.01 and 0.062±0.01 % ID/g), confirming the specificity of the tracer for the GLP-1R. Decreased radiopharmaceutical uptake was also noted in the kidney, lung, and stomach which is consistent with the reported presence of GLP-1R in rat kidney, lung, brain, and stomach [15] .
The pancreatic uptakes of all four conjugates at 1 h after injection are shown in Fig. 5 Table S3 . Exendin-4 blocked pancreatic uptake of radiolabeled DO3A-VS-/NODA-VS-Cys40-exendin-4 Ex vivo autoradiography studies on excised rat pancreas slices were conducted to localize the accumulation and retention of labeled analogues. Similar to results from previous studies [10] , focal areas of radiopharmaceutical uptake were observed in the pancreas consistent with specific uptake by pancreatic β cells. With [
64 Cu]DO3A-VS/NODA-VS analogues, a clear delineation of pancreatic islets was observed (Fig. 6) . The signal intensity observed in [ 64 Cu]DO3A-VS-and NODA-VS-Cys 40 -exendin-4 pancreatic sections (9.9×10 7 and 5.2×10 7 counts/mm 2 , respectively) was blocked by the excess of unlabeled exendin-4 and exendin-(9-39)-amide (97.7, 97.4, 96.2, and 94.2 %) in the β cells ( Table 1 ). The [ 68 Ga]DO3A-VS-/NODA-VS-exendin-4 derivatives showed less contrast (Fig. S2) -exendin-4 uptake and the extent of blocking by exendin-4 were compared. Although the kidney and lung uptakes were higher than the uptake from the pancreas, we were able to distinguish the pancreatic uptake in these rat images using the sagittal projection with a PET threshold of 17,300-52,800 Bq/ml (1427-1468 nCi/cc). The excess of unlabeled exendin-4 demonstrated the in vivo specific binding of the 64 Cu/ 68 Ga radioligands to the pancreatic GLP-1R. Radioligand uptake in the lungs and stomach was also completely reduced as observed in the biodistribution studies. This confirms the distribution of GLP-1 receptors in the rat lung and stomach. To our knowledge, this is the first example of exendin-4 pancreatic uptake visualized in a rat model using Cu-64 and Ga-68 radiolabeled analogues for in vivo imaging.
Discussion
GLP-1R agonist PET ligands have shown promise for the in vivo determination of BCM. Several DOTA and DO3A functionalized exendin-4 analogues labeled with radionuclides have been reported [10, 26, 29] . However, the pancreas was not imaged in small animal models due to high kidney uptake and the low contrast between target [27, 30] . In this report, we successfully imaged pancreatic β cells in normal SD male rats using DO3A and NODA functionalized exendin-4 analogues radiolabeled with Cu-64 and Ga-68 PET isotopes. Exendin-4 has ∼10-fold greater binding affinity for GLP-1R than the truncated antagonist exendin-(9-39)-amide [15] . A radiopharmaceutical based on the agonist exendin-4 is likely to be the optimal choice to measure β cell mass due to superior ligand affinity and the potential for radiotracer accumulation in the β cell by receptor internalization following agonist stimulation. In this study, a GLP-1R agonist and antagonist were both used as blocking agents to demonstrate the GLP-1R specificity of the exendin-4 based PET ligands.
In Recent publications have described the challenges of imaging β cells using GLP derivatives in small animal models [27, 30] . Several researchers have opted for models employing larger animals due to the ease of organ localization. Although pig and canine pancreata have larger volumes, the rat is a desirable model for imaging due to greater β cell density [41] . However, the most challenging aspect of imaging small animals is the higher uptake observed in the kidney which may obscure the pancreas. In order to visualize pancreas despite the high renal uptake, a PET threshold of 17,300-52,800 Bq/ml (1427-1468 nCi/cc) was utilized to highlight the contrast of pancreatic uptake. As shown in Fig. 7 , the sagittal images clearly indicate the distinctive difference between the kidney uptake and the pancreatic uptake. 40 -exendin-4 radiopharmaceuticals were prepared with 998 % purity and 518.7±3.7 Ci/mmol (19.19±0.14 TBq/ mmol) specific activity. The radiometal conjugates were very stable in rat serum in vitro. Biodistribution studies confirmed that all compounds had peak pancreas uptake at 1-h post injection. Blocking studies confirmed that the uptake of the radioligands by the pancreas was due to specific GLP-1R binding. Pancreatic uptake of the radioligands was imaged in vivo in rats and visualized with sagittal projection and the threshold of 17,300-52,800 Bq/ml (1427-1468 nCi/cc). [ 68 Ga]NODA-VS-Cys 40 -exendin-4 had the highest accumulation and specific binding to the GLP-1R of the four conjugates examined. These Cu-64-and Ga- 68-labeled DO3A-VS/NODA-VS-tagged exendin-4 analogues are PET imaging agents specific for GLP-1R which have potential utility for the quantification of BCM.
Conclusions
